Novartis' Pelacarsen Trial Fails to Improve Cardiovascular Outcomes

Novartis and Ionis Pharmaceuticals announced a setback in their cardiovascular clinical trial for pelacarsen. Despite successfully reducing lipoprotein(a) (Lp(a)) levels, the drug did not demonstrate a meaningful improvement in cardiovascular outcomes. This outcome challenges the hypothesis that lowering Lp(a) directly reduces the risk of heart attacks and strokes, potentially impacting the future development of other Lp(a)-targeting drugs.